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LETTERS TO THE EDITOR
Prognostic Significance of Immune Activation
After Acute Coronary Syndromes
We read with great interest the study by Maekawa et al. (1) in a
recent issue of the Journal. The article reports that the peripheral
peak monocyte count is associated with adverse cardiac outcome
during a 33-month follow-up period. The authors could demon-
strate that peripheral monocytosis represents an independent
determinant of adverse cardiac outcome, including pump failure,
left ventricular aneurysm, hospital readmission for heart failure,
recurrent myocardial infarction and cardiac deaths, including
sudden deaths.
Elevated C-reactive protein, as a marker of inflammation,
measured early after the onset of acute ischemia (2), has been
found to correlate with higher risk for cardiac events in patients
with acute myocardial infarction (AMI) (3,4). In acute coronary
syndromes (ACS), the release of different cytokines activates
cellular defense (5). Infiltration of neutrophils and monocytes/
macrophages is detected in the myocardium after AMI. Macro-
phages activated by interferon gamma synthesize metalloprotein-
ases and neopterin, a pteridine derivative and a byproduct of the
guanosine triphosphate-biopterin pathway (6), that has been used
as an immune marker (7). We (8) and others (9, 10) previously
demonstrated that neopterin levels significantly increase in patients
with ACS shortly after the onset of ischemic symptoms. In our
study (8), there was no correlation between neopterin and creatine
kinase (CK), CK-MB isoenzyme or troponin I as markers for the
extent of the myocardial injury.
The prognostic significance of the degree of increased neopterin
levels after ACS has not yet been evaluated (to our knowledge).
The 25 patients with ACS (18 men, 7 women; mean age, 68.5 
14.3 years; range, 40 to 86 years) included in our study (8) were
followed up for 22 (3) months. Six patients (24%) had adverse
cardiovascular events (defined as cardiovascular death, recurrent
AMI, stroke, hospital readmission for heart failure) during follow-
up. Neopterin levels measured 72 hours after the onset of symp-
toms of ACS were 7.13 (2.34) nmol/l in patients without
cardiovascular events, and 10.6 (2.56) nmol/l in patients with
adverse cardiovascular events during follow-up, respectively (p 
0.01).
Therefore, our data support and expand the results from
Maekawa et al. (1) that the degree of inflammatory response and
immune activation after ACS, in particular the monocyte/
macrophage-mediated process, predicts adverse cardiovascular
events during follow-up independent of the extent of the myocar-
dial injury.
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The Use of the Grant
Method to Interpret Electrocardiograms
Many interpreters of electrocardiograms (ECGs) will agree with
the statements made in the article by Yamaji et al. (1). The authors
used pattern recognition to explain their findings. I wish to use the
same ECGs that they published, but offer the use of basic
principles, including vector concepts, to explain the abnormalities
shown in the ECGs (2).
Einthoven’s law and equilateral triangle, though not absolutely
perfect, have stood the test of time when used for clinical purposes.
Accordingly, an ECG deflection in lead I, plus the deflection in
lead III, equals the deflection in lead II. It is also accepted that the
deflection in lead aVR, plus the deflection in lead aVL, plus the
deflection in aVF equals zero. All six of the extremity lead
electrodes are electrically equal distance from the heart; therefore,
each lead is equally capable of recording the electrical forces made
by the entire heart. The only reason the deflections are different in
different extremity leads is that the electrodes of the various leads
have a different view of the electrical forces that produce the
deflections. Accordingly, no secret information belongs to a
specific extremity lead. A metaphor might be as follows: photo-
graphs of a person made in the frontal plane from six different, but
from distant vantage points would all be different, but there is only
one person.
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